Bristol Myers Squibb to Open New Cell Therapy Facility in Massachusetts
The new facility is part of Bristol Myers Squibb’s investment into the clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.
Bristol Myers Squibb announced on Feb. 23, 2021 that construction has begun on its new cell therapy manufacturing facility in Devens, MA.
Located on the company’s current 89-acre Devens campus, the 244,000-ft2 facility will have the ability to handle the quick ramp-up of capacity for clinical and commercial cell therapy products, Bristol Myers Squibb said in a company press release. The new facility is part of Bristol Myers Squibb’s investment into the clinical and commercial manufacturing of cell therapies for patients with aggressive hematological cancers.
“Bristol Myers Squibb is at the forefront of manufacturing innovations, and we are proud that our new cell therapy facility in the Boston area will include many next generation technologies and the latest integrated digital systems,” said Ann Lee, PhD, head, Cell Therapy Development and Operations, Bristol Myers Squibb, in the press release.
Source: Bristol Myers Squibb
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
